Teva and Medincell's schizophrenia drug meets main goal of late-stage study

Medincell SA

08/05/2024 11:36

May 8 (Reuters) - Teva Pharmaceuticals  TEVA.TA 
 TEVA.K  and partner Medincell  MEDCL.PA  said on Wednesday
their experimental schizophrenia drug had met its main goal in a
late-stage study. 

 (Reporting by Puyaan Singh; Editing by Devika Syamnath)
 ((Puyaan.Singh@thomsonreuters.com;))